-transparent.png){kind=logo}
Standardization of determinations for prostate specific antigen (PSA) has become an important issue due to the widespread use of these determinations for prostate cancer screening. Standardization of this assay is complicated due to the occurrence of two major forms of PSA in serum, the free antigen and a complex between PSA and alpha 1-antichymotrypsin (PSA-ACT). These two forms of PSA are recognized differently by different antibodies, but by careful selection of antibodies, it is possible to design methods that measure each form equally. It is suggested, that standards for PSA and PSA-ACT should be prepared and established as international standards. Furthermore, reference methods should be established on the basis that these standards and carefully selected reference antibodies.
U H Stenman, and
J Leinonen, and
W M Zhang
August 1998,
Nihon rinsho. Japanese journal of clinical medicine,
U H Stenman, and
J Leinonen, and
W M Zhang
January 1964,
Duodecim; laaketieteellinen aikakauskirja,
U H Stenman, and
J Leinonen, and
W M Zhang
December 2013,
Best practice & research. Clinical endocrinology & metabolism,
U H Stenman, and
J Leinonen, and
W M Zhang
April 1993,
Cancer,
U H Stenman, and
J Leinonen, and
W M Zhang
June 1944,
Canadian Medical Association journal,
U H Stenman, and
J Leinonen, and
W M Zhang
July 1974,
JAMA,
U H Stenman, and
J Leinonen, and
W M Zhang
February 1986,
Clinical chemistry,
U H Stenman, and
J Leinonen, and
W M Zhang
September 1946,
Philadelphia medicine,
U H Stenman, and
J Leinonen, and
W M Zhang
July 2004,
Rinsho byori. The Japanese journal of clinical pathology,
U H Stenman, and
J Leinonen, and
W M Zhang
January 2010,
Urologiia (Moscow, Russia : 1999),
